FDA warned Singapore website d-pharmacy.com for selling unapproved prescription opioids, benzodiazepines, and stimulants to U.S. consumers.
What happened
FDA reviewed the website www.d-pharmacy.com and found it offering opioids, benzodiazepines, and Schedule II stimulants for sale to U.S. consumers. FDA said these are unapproved new drugs (not FDA-approved for those labeled uses) and misbranded (labeling lacks adequate directions, and prescription drugs are offered without a prescription). There was no inspection; FDA acted on its website review.
What FDA found
FDA says the website sells opioids, benzodiazepines, and stimulants that are not FDA-approved for the labeled uses.
FD&C Act §§ 301(d), 505(a) [21 U.S.C. §§ 331(d), 355(a)]FDA says the labeling does not give adequate directions for a layperson to use the prescription drugs safely.
FD&C Act § 502(f)(1) [21 U.S.C. § 352(f)(1)]FDA says the site offers prescription drugs for sale without requiring a prescription.
FD&C Act §§ 503(b)(1), 301(k) [21 U.S.C. §§ 353(b)(1), 331(k)]FDA says offering these drugs for sale causes misbranded drugs to enter interstate commerce.
FD&C Act § 301(a) [21 U.S.C. § 331(a)]
What FDA wants
FDA asks www.d-pharmacy.com to stop offering unapproved and misbranded drugs to U.S. consumers. It asks for a written reply within 15 working days describing corrective steps and how recurrence will be prevented.
Who should pay attention
- U.S. consumers who buy prescription drugs online
- online pharmacies selling to U.S. customers
- companies that ship or advertise prescription drugs to U.S. consumers
This is a summary. Read the original letter on fda.gov.